Sho Kuriyama

Dr. Sho Kuriyama

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
RORyo Ohta
Ryo Ohta
TYTakeshi Yamada
Takeshi Yamada
HSHiromichi Sonoda
Hiromichi Sonoda
AMAkihisa Matsuda
Akihisa Matsuda
Seiichi ShinjiSeiichi Shinji
Seiichi Shinji
HYHiroshi Yoshida
Hiroshi Yoshida

25 February 2022 in Journal of Nippon Medical School
Verified
Journal Article
Open access
PDF file
MNMaki Nakai
Maki Nakai
TYTakeshi Yamada
Takeshi Yamada
KSKenta Sekiya
Kenta Sekiya
ASAi Sato
Ai Sato
MHMeishi Hankyo
Meishi Hankyo
HTHiroyuki Takei
Hiroyuki Takei
Background: PIK3CA is associated with tumor progression, and the prevalence of its mutation is high in breast cancer. Liquid biopsy offers convenient, non-invasive, and real-time insight into genetic alternation. In this study, we attempted to detect PIK3CA mutations in breast cancer patients through liquid biopsy.Methods: We recruited patients with histologically confirmed breast cancer with distant metastases between April 2020 and September 2020. Circulating DNA was extracted from plasma (ctDNA) and exosomes (exoDNA). PIK3CA mutations (exons 9 and 20) were analyzed by droplet digital PCR.Results: Of a total of 52 patients recruited, 16 had PIK3CA mutations in their tumor tissue or blood, which comprised 9 with exon 9 mutations (E542K and E545K) and 8 with exon 20 mutations (H1047L and H1047R). In 8 (15%) of the 52 patients, PIK3CA mutations were detected by liquid biopsies using ctDNA in 5 (9%), exoDNA in 6 (11%), and both ctDNA and exoDNA in 3 (6%). Of the 8 patients with PIK3CA mutations detected by liquid biopsies, 3 had no PIK3CA mutations in the primary tumors.Conclusions: PIK3CA mutations can be detected using liquid biopsy even in patients with no PIK3CA mutations in their primary tumors; thus, combination analysis using tissue and liquid biopsies can provide clinically useful information for patients with breast cancer.

1 November 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
HSHiromichi Sonoda
Hiromichi Sonoda
TYTakeshi Yamada
Takeshi Yamada
AMAkihisa Matsuda
Akihisa Matsuda
RORyo Ohta
Ryo Ohta
Seiichi ShinjiSeiichi Shinji
Seiichi Shinji
HYHiroshi Yoshida
Hiroshi Yoshida

2 February 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
KUKoji Ueda
Koji Ueda
TYTakeshi Yamada
Takeshi Yamada
RORyo Ohta
Ryo Ohta
AMAkihisa Matsuda
Akihisa Matsuda
HSHiromichi Sonoda
Hiromichi Sonoda
HYHiroshi Yoshida
Hiroshi Yoshida

10 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
TNTakayoshi Nishimoto
Takayoshi Nishimoto
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
TYTakeshi Yamada
Takeshi Yamada
SKSho Kuriyama
Sho Kuriyama
AHAitoshi Hoshimoto
Aitoshi Hoshimoto
MAMasanori Atsukawa
Masanori Atsukawa
Background/Objectives: The Wnt signaling pathway is pivotal in the adenoma–carcinoma sequence; however, its role in small bowel adenocarcinoma (SBA) remains insufficiently characterized. We analyzed the clinicopathological significance of Wnt pathway-related gene mutations and the expression of downstream or associated proteins in SBA. Methods: Immunohistochemical staining for β-catenin, cyclin D1, c-Myc, E-cadherin, and Wnt5a was performed in 75 primary SBA surgical specimens. Targeted next-generation sequencing was conducted in 48 of these cases. Results: The genomic alterations in the Wnt pathway were identified as APC (14.6%) and CTNNB1 (8.3%), with no overlap between the two mutations. Aberrant (reduced membranous and/or nuclear) expression of β-catenin was observed in 37% of cases. Cyclin D1 and c-Myc were expressed in 60% and 41% of cases, respectively. Aberrant expression of β-catenin and/or Wnt5a was present in 60% of cases and was correlated with cyclin D1 and c-Myc expression. Mutations in APC and CTNNB1 were found in intestinal- and gastrointestinal-type SBAs, but were absent in gastric-type SBA. In intestinal-type SBA, the mutation frequency of APC and CTNNB1 was 39%, closely aligning with the 45% aberrant expression of β-catenin. Aberrant expression of β-catenin and/or Wnt5a, a ligand of the noncanonical Wnt pathway, was detected in 60% of cases and showed a correlation with both cyclin D1 and c-Myc expression. Conclusions: These findings suggest that both canonical and noncanonical Wnt pathway-related proteins are involved in SBA carcinogenesis and progression. Notably, the canonical Wnt pathway appears to play a predominant role in intestinal-type SBA.

6 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TNTakayoshi Nishimoto
Takayoshi Nishimoto
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
TYTakeshi Yamada
Takeshi Yamada
SKSho Kuriyama
Sho Kuriyama
AHAitoshi Hoshimoto
Aitoshi Hoshimoto
MAMasanori Atsukawa
Masanori Atsukawa
Background/Objectives: The Wnt signaling pathway is pivotal in the adenoma-carcinoma sequence; however, its role in small bowel adenocarcinoma (SBA) remains insufficiently characterized. We analyzed the clinicopathological significance of Wnt pathway-related gene mutations and the expression of downstream or associated proteins in SBA. Methods: Immunohistochemical staining for β-catenin, cyclin D1, c-Myc, E-cadherin, and Wnt5a was performed in 75 primary SBA surgical specimens. Targeted next-generation sequencing was conducted in 48 of these cases. Results: Genomic alterations in the Wnt pathway were identified as APC (14.6%) and CTNNB1 (8.3%), with no overlap between the two mutations. Aberrant (reduced membranous and/or nuclear) expression of β-catenin was observed in 37% of cases. Cyclin D1 and c-Myc were expressed in 60% and 41% of cases, respectively. Aberrant expression of β-catenin and/or Wnt5a was present in 60% of cases and correlated with cyclin D1 and c-Myc expression. Mutations in APC and CTNNB1 were found in intestinal and gastrointestinal-type SBAs but were absent in gastric-type SBA. In intestinal-type SBA, the mutation frequency of APC and CTNNB1 was 39%, closely aligning with the 45% aberrant expression of β-catenin. Aberrant expression of β-catenin and/or Wnt5a, a ligand of the noncanonical Wnt pathway, was detected in 60% of cases and showed correlation with both cyclin D1 and c-Myc expression. Conclusions: These findings suggest that both canonical and noncanonical Wnt pathway-related proteins are involved in SBA carcinogenesis and progression. Notably, the canonical Wnt pathway appears to play a predominant role in the intestinal-type SBA.